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1. Introduction  
Atherosclerosis is a progressive chronic inflammatory disease characterised by the 
accumulation of lipids and fibrous elements in large arteries and increasingly threatens 
human health worldwide. Atherosclerotic lesion formation is a complex process which can 
proceed over decades. A number of different factors contribute to the formation of 
atherosclerotic lesions including the accumulation of lipids, activation of T-cells, 
transformation of macrophages into foam cells and proliferation of smooth muscle cells. The 
earliest events that lead to lesion formation are still very much under investigation. A 
number of risk factors have been identified that contribute to the pathogenesis of 
atherosclerosis, including hypertension, smoking, increased concentrations of plasma 
cholesterol, diabetes, obesity, age and male gender. All these risk factors can influence 
endothelial cell function resulting in increased permeability, increased adhesion of 
leukocytes and the expression of procoagulant molecules.  
Intercellular adhesion molecule-1 (ICAM-1, CD54) is an immunoglobulin (Ig)-like cell 
adhesion molecule expressed by several cell types including leukocytes and endothelial 
cells. It is constitutively expressed at low levels on endothelial cells and leukocytes and up-
regulated following exposure to pro-inflammatory stimuli. ICAM-1 is important for the firm 
arrest and transmigration of leukocytes out of blood vessels and into tissue, as well as 
immunological synapse formation during T cell activation. It is present in atherosclerotic 
lesions and is involved in the progression of atherosclerotic lesions. We and others have 
shown that crosslinking of ICAM-1 on the cell surface leads to “outside in” signal 
transduction and to result in the initiation of several pro-inflammatory signalling cascades 
and rearrangement of actin cytoskeleton, leading to speculation that ICAM-1 “is more than 
just glue”. 
A soluble ICAM-1 molecule has been identified in serum, consisting of all five extracellular 
Ig-domains of membrane-bound ICAM-1-molecule, but lacking the transmembrane and 
cytoplasmic domains. sICAM-1 is present in normal human serum, whilst elevated sICAM-1 
have been found in serum from patients with cardiovascular disease, cancer, autoimmune 
disease and several studies have correlated serum levels of sICAM-1 with severity of 
disease. Several studies have shown that sICAM-1 is able to bind to ligands of ICAM-1 and 
a yet unknown receptor and is able to instigate signalling cascades. Here, we present our 
recent data which suggests that sICAM-1 acts as a pro-inflammatory agent when endothelial 
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cells are subjected to prolonged arterial shear forces, including initiation of cytokine and 
chemokine expression, which could lead to monocyte attraction to inflamed regions of the 
vasculature.   
2. Atherosclerosis  
Atherosclerosis is a protracted, complex process, which takes place over several decades. 
The main contributing factors are lipid accumulation, activation of T-cells, transformation of 
macrophages into foam cells and the proliferation of underlying smooth muscle cells (Ross 
1999; Lusis 2000).  
Many theories have been discussed over the years about the initiation phase of 
atherosclerosis. William and Tabas suggested that a loss of endothelial cells within the blood 
vessel wall allowed increased permeability of leukocytes and lipoproteins into the 
subendothelial space and caused plaque formation (Williams and Tabas 1995). However, 
studies showing the presence of an intact endothelial cell layer at the site of plaque 
formation rejected the “endothelial cell denudation” theory. The theory was replaced by the 
“response to injury” hypothesis by Ross (Ross and Glomset 1974; Ross 1999). Ross suggested 
that injury of the endothelium lead to endothelial cell dysfunction and altered smooth 
muscle cell behaviour. Currently, more evidence points towards the “response to retention” 
hypothesis, which identified atherogenic lipoproteins as a key initiation step (Schwenke and 
Carew 1989; Schwenke and Carew 1989). The direct binding of these lipoproteins to the 
endothelium and the subsequent accumulation within the subendothelial space is thought 
to trigger endothelial cell activation, which is followed by an inflammatory response 
(Williams and Tabas 1995). 
Apart from lipid there are a number of other factors that have been associated with 
accelerated cardiovascular disease and could contribute to vascular inflammation. It is 
widely appreciated that there is a greatly increased risk of cardiovascular disease with 
increase in body mass index independent of serum cholesterol (Lavie , Milani et al. 2009), 
and that patients with type II diabetes, chronic renal disease (Karalliedde, and Viberti 2004), 
and autoimmune disorders such as rheumatoid arthritis or lupus (Frostegård 2011) are far 
more likely to develop atherosclerosis independent of cholesterol and other traditional risk 
factors. A number of chronically infectious agents have also been linked to atherosclerosis 
including Chlamydia pneumoniae (Laurila, Bloigu et al. 1997) and Helicobacter pylori 
(Hoffmeister, Rothenbacher et al. 2001). These associations are likely to be due to an increase 
in systemic inflammation, characterised by chronically elevated levels of CRP and pro-
inflammatory cytokines such as TNF-ǂ, IL-1, IL-6. These circulating factors are all known to 
contribute to endothelial activation in vitro and to the expression of genes involved in 
vascular inflammation and atherosclerosis progression in vivo (Hansson 2009). 
The earliest event visible within the blood vessel wall is the appearance of a “fatty lesion”. 
These lesions can be found at branches, bifurcations and curvations of the arterial blood vessel 
walls (Lusis 2000). At these locations a disturbed flow pattern of the blood can be detected 
compared with the parallel (laminar) flow seen at “tubular” blood vessel sections. The 
disturbed shear stress at curved blood vessel locations activates endothelial cells and results in 
accumulation of lipoproteins (LDL), and activated macrophages within the subendothelial 
spaces. Skalen et al. (Skålén, Gustafsson et al. 2002) showed that lipoproteins initially bind to 
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negatively charged sulphate groups on proteoglycans in the artery wall before translocating to 
the subendothelial space. The significance has been demonstrated in mice deficient in 
proteoglycans, which develop a reduced number of atherosclerotic lesions (Skålén, Gustafsson 
et al. 2002). Native LDL contributes to the inflammation at lesion site by undergoing 
modification by oxidation, lipolysis or proteolysis before being taken up by macrophages 
(reviewed by (Lusis 2000)). The uptake and accumulation of modified lipoproteins transforms 
the macrophages into foam cells, which are retained within the fatty streak. 
 
Fig. 1. Schematic cartoons showing healthy, tubular blood vessel (A) and curved blood 
vessel with plaque formation in process (B).  
Oxidised LDL also contributes to the progression of the early lesion by itself stimulating 
endothelial cells to produce pro-inflammatory molecules, which leads to the recruitment of 
further immune cells. One important molecule released is the chemokine CCL-2 (MCP-1), 
which is responsible for recruiting monocytes to the lesion site (Gerszten, Garcia-Zepeda et 
al. 1999). Activated endothelial cells upregulate adhesion molecules including ICAM-1 on 
their cell surface facilitating transmigration of further leukocytes. The inflammatory 
environment within the lesion leads to the migration and proliferation of smooth muscle 
cells, infiltration of immune cells including B-cells, dendritic cells, mast cells and T-cells as 
well as elaboration of a collagen-rich matrix (Hansson and Libby 2006). The advanced lesion 
consists of a core containing foam cells, lipids and necrotic debris, which is surrounded by 
smooth muscle cells. The growth is asymmetrical protruding into the lumen and resulting in 
further blood flow changes. The exact composition of the plaque dictates the stability of the 
plaque. The fibrous cap, which is produced by smooth muscle cells and influenced by 
immune cells, prevents the contact between blood components and pro-thrombotic material 
within the lesion. Thrombus formation occurs once the fibrous cap raptures and coagulation 
factors come into contact with contents of the lesion (Hansson and Libby 2006).  
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2.1 Role of endothelium  
All large blood vessels, including the vessels of the arterial tree, are made up of several 
distinct tissue layers: the intima, media and adventitia. The intima is the inner lining and is 
formed of a single continuous layer of endothelial cells on the luminal side with a 
specialised subendothelial basement membrane and the internal elastic lamina. Beneath this 
vascular smooth muscle cells, elastic and collagen fibres, together with the external elastic 
lamina, make up the media. A connective tissue sheath, which may be vascularised with 
vasa vasorum, forms the outer layer, the adventitia. 
The vascular endothelium, located on the luminal side of the intima, functions as a highly 
selective barrier, and its restrictive permeability is a vital component in healthy blood 
vessels. However, studies during the last 20 years have shown that the endothelium does 
not act as a passive barrier as previously thought, but is highly dynamic and controls a 
variety of functions. It is involved in the regulation of vessel tone, coagulation and 
fibrinolysis, leukocyte adhesion, fluid and solute exchange and the control of smooth  
muscle cell growth (Ross 1999; Lusis 2000). Indeed endothelial dysfunction contributes to 
many cardiovascular conditions including atherosclerosis, hypertension, stroke, 
inflammation, vasospastic disorders, diabetic microangiopathy, autoimmune disease, 
hypercholesterolemia, thrombosis and tumour growth (reviewed by (Lusis 2000)). 
Endothelial cells react to a number of different stimuli, they are not only exposed to humoral 
factors from the circulation, but they are also subject to a variety of biomechanical stimuli. 
They differ depending on their location within the vascular beds and exhibit varying 
phenotypes. They are responsive to the environment of their local tissue and change barrier 
function accordingly to requirement of the underlying tissue. 
Endothelial cells form a tight monolayer with well organised cell-to-cell junctions. These 
junctions are held together strongly by homo- and heterophilic binding of a number of key 
adhesion molecules expressed on neighbouring endothelial cells. The junctions play a vital 
role not only in permeability control, but also regulate leukocyte trans-endothelial migration 
and endothelial cell growth. The most important molecules involved in the cell-to-cell 
junction are considered to be PECAM-1 and VE-Cadherin.   
2.2 Importance of flow  
Cyclic stretch, fluid shear stress and hydrostatic pressure are the three main hemodynamic 
forces present within the blood vessel (Gimbrone, Topper et al. 2000). The importance of 
each force varies between the different cell types within the blood vessel wall. Smooth 
muscle cells mainly respond to cyclic stretch, whereas shear stress is the major force 
experienced by endothelial cells (Li, Haga et al. 2005). Shear stress acts parallel to the vessel 
wall within the lumen. It has a uniform, laminar pattern in “linear”, unbranched areas of the 
vasculature. Depending on the location and type of the blood vessel, the (positive) shear 
stress values range between 10-40 dynes/cm2 in the arterial network, and 1-20 dynes/cm2 in 
the venular microcirculation (Surapisitchat, Hoefen et al. 2001; Lehoux, Castier et al. 2006). 
Endothelial cells exposed to prolonged laminar shear stress align and elongate in the 
direction of flow by reorientating their actin cytoskeleton, microtubules and intermediate 
filaments (Resnick, Yahav et al. 2003). This arrangement reduces the mechanical load 
experienced by endothelial cells and induces a quiescent state in which apoptotic, 
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inflammatory and atherogenic genes are suppressed (Resnick, Yahav et al. 2003). 
Endothelial cells themselves secrete a number of factors which contribute to this quiescent 
state, including the vasodilator nitric oxide (NO) and the vasorelaxant PGI2.. NO is released 
into the lumen of the blood vessel where it acts to inhibit the attachment of platelets and 
leukocytes onto the luminal surface of endothelial cells. NO is also secreted into the basal 
side and prevents growth of smooth muscles cells underneath the endothelium. NO has also 
been reported to suppress the activation of transcription factors for adhesion molecules 
including ICAM-1 (De Caterina, Libby et al. 1995; Lindemann, Sharafi et al. 2000). The lack 
of expressed adhesion molecules on the endothelium prevents vascular inflammation and 
irregular cell proliferation (Figure 2a).  
Sites exposed to steady laminar flow with high shear stress are atheroprotective (Gimbrone, 
Topper et al. 2000). At bifurcations and bends in the vasculature the laminar flow pattern 
becomes disrupted and creates sites with recirculating blood flow. The shear stress values 
vary from negative, to zero to positive values (Resnick, Yahav et al. 2003). Sites experiencing 
turbulent and disturbed flow are prone to develop atherosclerosis (Figure 2b) (Gimbrone, 
Topper et al. 2000).  
Endothelial cells have been shown to possess a variety of mechanoreceptors, which not only 
sense shear stress but are able to react to changes by influencing gene expression. Several 
different molecules have been identified on endothelial cells as mechanoreceptors including 
two members of the integrin family, vß3 (Tzima, del Pozo et al. 2001) and 5ß1 (Chen, Li et 
al. 1999). Changes in shear stress lead to integrin clustering, thereby triggering the 
recruitment of shc to their cytoplasmic tails. This results in the initiation of signal cascades, 
which leads to phosphorylation of MAPK-kinases ERK and JNK (reviewed by (Shyy and 
Chien 2002)). One important example of a receptor tyrosine kinase acting as a 
mechanosensor on the endothelium is VEGFR-2 (Chen, Li et al. 1999). Rapid and transient 
phosphorylation of the tyrosine residues within the cytoplasmic tail of VEGFR-2 and the 
association with shc has been observed upon exposure to shear stress (Chen, Li et al. 1999). 
Another important group of mechanoreceptors are G-proteins and /or G-protein coupled 
receptors. Gudi and colleagues (Gudi, Clark et al. 1996) reported that G-protein activation 
takes place immediately upon exposure. In addition, several ion channels that are sensitive 
to shear stress have been identified. Studies have shown that K+ channels induce NO when 
exposed to shear stress in bovine aortic endothelial cells (Ohno, Cooke et al. 1995; 
Helmlinger, Berk et al. 1996; Yamamoto, Korenaga et al. 2000). The glycoprotein PECAM-1 
(CD31), which is involved in endothelial cell to cell adhesion, has also been shown to be 
sensitive to changes in shear stress. It is thought that fluid shear stress disrupts the 
conformation of the cytoplasmic tail revealing two tyrosine residues and enabling signal 
transduction (Fujiwara, Masuda et al. 2001; Osawa, Masuda et al. 2002). Recently, monocilia 
on endothelial cells in chick embryos and primary cilia on human vascular endothelial cells 
have been found in regions exposed to low or oscillatory shear stress. These have been 
proposed to contribute to endothelial activation and dysfunction (Van der Heiden, 
Groenendijk et al. 2006; Van der Heiden, Hierck et al. 2008). Caveolae have also been 
suggested to act as mechanoreceptors. Caveolae are plasma membrane invaginations, rich in 
cholesterol and identified by the protein marker caveolin-1. It is thought that signalling is 
initiated by the shear stress- induced movements of these rigid structures, which contain G-
coupled receptors, Ca2+ channels, VEGFR-2 and eNOS (Frank and Lisanti 2006). Another 
possible mechanosensitive structure on the luminal surface of endothelial cells may be the 
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polysaccharide network that makes up the glycocalyx. The glycocalyx is known to act as a 
selectively permeable barrier for macromolecules based on their size and charge. However, 
it is also thought to sense mechanical forces and transduce the signals into intracellular 
responses (Florian, Kosky et al. 2003; Thi, Tarbell et al. 2004). 
 
Fig. 2. Cartoon showing the different flow patterns experienced by endothelial cells. Parallel, 
laminar shear stress is present in unbranched, tubular parts of the blood vessel (A). 
Disturbed shear stress can be found at bends or bifurcation of blood vessels (B).  
Depending on the type of blood vessel and the nature and strength of shear stress that the 
endothelium is subjected to in different locations in the vasculature, it is likely that a range 
of different mechanoreceptors are involved in mechanosensing and signal transduction. 
More research is required to identify the exact roles of each mechanosensor, the signalling 
pathways they activate and their contribution to endothelial activation or quiescence.  
2.3 Endothelial cell inflammatory responses  
There are a number of features of endothelial cell dysfunction including changes on the cell 
surface such as upregulation of adhesion molecules, exposure of pro-coagulant molecules, 
loss of highly selective barrier function and changes in vascular tone (reviewed by 
(Malyszko 2010)).  
In quiescent, non-inflamed endothelial cells, NO prevents many responses leading to 
dysfunction and inflammation. However, once NO production is disrupted the brakes are 
removed from many of these harmful pathways. Oxidative stress within the endothelium 
has been reported as one of the key consequences of disrupted NO production, due to the 
formation of reactive oxygen species (ROS) and peroxynitrites. These harmful metabolic by-
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products can initiate pro-inflammatory signalling cascades, leading to upregulation of 
adhesion molecules including ICAM-1 and VCAM-1, chemokine and cytokine secretion. 
This contributes to increased monocyte adhesion and trans-endothelial migration. In 
addition ROS are responsible for oxidation of circulating lipoproteins. Together these events 
are very important for initiation of fatty streak formation in early atherosclerosis (reviewed 
by (Collins and Tzima 2011)). 
3. ICAM-1  
3.1 Structure of ICAM-1  
Intracellular adhesion molecule 1 (ICAM-1, CD54) is a type I transmembrane glycoprotein, 
which belongs to the immunoglobin (Ig)-superfamily. It is constitutively expressed at basal 
levels on endothelial cells and leukocytes, but is upregulated by inflammatory stimulators 
such as TNF- (Pober, Gimbrone et al. 1986), IFN-Ǆ (Dustin, Rothlein et al. 1986), IL-1 
(Dustin, Rothlein et al. 1986) and LPS (Sampath, Kukielka et al. 1995) as well as shear stress 
(Nagel, Resnick et al. 1994). Upregulation of ICAM-1 is inhibited by glucocorticoids 
(Cronstein, Kimmel et al. 1992) and by IL-4 (Renkonen, Mattila et al. 1992). 
ICAM-1 is encoded on seven exons with exon 1 encoding the signal sequence, exon 2 to 6 
each extracellular Ig-domain and exon 7 the transmembrane and intracellular domains. The 
molecular weight ranges between 80-114kDa as the level of glycosylation varies heavily 
between different cell types. The ICAM-1 extracellular domain consists of 453 mainly 
hydrophobic amino acids, which form five Ig-domains with ǃ-sheet structure, each Ig-
domain stabilised by disulfide bonds (Figure 3). The Ig-domains are followed by a single 
hydrophobic transmembrane region and a short 28 amino acid cytoplasmic domain, which is 
lacking any conventional signalling motifs. Tyrosine residues within the cytoplasmic tail have 
been shown to be important for intracellular ICAM-1 signalling (Tsakadze, Sen et al. 2004).  
  
Fig. 3. Cartoon showing membrane bound ICAM-1 with its five Ig-domains (D1 – D5) and 
ligands LAF-1, mac-1, plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) and 
human rhinovirus (hRV). Arrow indicates membrane region, which becomes cleaved off by 
proteases or alternative splicing releasing solube ICAM-1 (sICAM-1). (Adapted from 
Lawson and Wolf 2009 and Van de Stolpe and Van der Saag 1996).  
Studies by Kirchhausen et al. (Kirchhausen, Staunton et al. 1993) have shown that ICAM-1 
has a characteristic 140° bend between domain 3 and domain 4. This bend enables formation 
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of homo dimers and multimers resulting in a “YYYY” configuration. The dimerisation is not 
required for ligand binding but increases binding avidity. The resulting stronger and 
prolonged interaction with its ligands is especially beneficial during antigen presentation 
and leukocyte transmigration. 
3.2 Ligands for ICAM-1  
ICAM-1 has several ligands including the membrane-bound ǃ2 integrin receptors 
CD11a/CD18 (LFA-1) and CD11b/CD18 (mac-1) present on leukocytes (Marlin and 
Springer 1987; Staunton, Marlin et al. 1988; Smith, Marlin et al. 1989) and fibrinogen 
(Languino, Plescia et al. 1993; Languino, Duperray et al. 1995; van de Stolpe and van der 
Saag 1996). A major group of human rhinovirus (Greve, Davis et al. 1989; Staunton, 
Merluzzi et al. 1989) and erythrocytes infected with plasmodium falciparum (Ockenhouse, Ho 
et al. 1991; Ockenhouse, Tegoshi et al. 1992) are also able to bind to ICAM-1. 
The integrin ligands of ICAM-1 are members of the type I transmembrane heterodimeric 
glycoprotein family and consist of two non-convalently linked chains. LFA-1 and mac-1 
possess the same ǃ2-integrin subunit (CD18) but different -chains namely L (CD11a) for 
LFA-1 and M (CD11b) for mac-1. Both integrins bind via an “inserted” (I) domain on the 
respective -chain to an acidic residue on ICAM-1. LFA-1 binds to glutamic acid (residue 34) 
on ICAM-1 in the presence of magnesium and calcium ions. The ligand binding results in a 
reorientation of glutamic acid positioned within the third domain (residue 241) and the 
formation of a critical salt bridge with lysine (residue 39). The binding site for integrin mac-1 
is located within the third domain of ICAM-1 and is dependent on the glycosylation level. 
High levels of N-linked oligosaccharides sterically and electrostatically hinder access to the 
binding site. As the level of glycosylation is dependent on cell type, different cell types will 
allow a diverse ligand binding pattern. Activation of the integrins is required before binding 
of LFA-1 or mac-1 to ICAM-1 can occur. On resting cells, integrins exhibit a low affinity 
conformation for ligand binding. Following “inside-out” signalling, a conformational 
change takes places exposing a high affinity ligand binding site. Integrins play an important 
role in the immune system as demonstrated in patients with type I leukocyte adhesion 
deficiency (LAD), a rare autosomal recessive disorder, which causes a complete lack of ǃ2 – 
integrins. This deficiency causes severe defects in the inflammatory immune system and 
leads to multiple, chronic and life-threatening bacterial infections (Blankenberg 2003). 
In addition to activated integrins, the majority of rhinovirus family (91 serotypes) and some 
members of the coxsackie virus A family bind ICAM-1 (Greve, Davis et al. 1989; Staunton, 
Merluzzi et al. 1989). The virus families bind to an epitope on domain one which lies 
directly next to LFA-1 (Staunton 1990) and overlaps with the one used by plasmodium 
falciparum infected erythrocytes (Ockenhouse, Betageri et al. 1992). Binding to ICAM-1 
initiates the entry of the virus into the host cell (Bella and Rossmann 1999).  
Another ligand, which has been shown to bind to ICAM-1 is fibrinogen (Altieri, Duperray et 
al. 1995). The plasma glycoprotein is involved in blood coagulation, inflammation and tissue 
repair (Tsakadze, Zhao et al. 2002). Its binding to ICAM-1 enables the adhesion of 
circulating platelets and inflammatory cells to the endothelium and fibrinogen deposition, 
which can lead to increased leukocyte transmigration, endothelial cell survival and 
vasocontriction (Tsakadze, Zhao et al. 2002).  
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3.3 Function of ICAM-1 
The main function of ICAM-1 is to provide firm adhesion, a characteristic which is pivotal in 
leukocyte transendothelial migration and antigen presentation. 
The leukocyte transmigration process, which is also called diapedesis, can be divided into 
four sequential, but overlapping steps as summarised in Figure 4 (Springer 1994): 
 
Fig. 4. Cartoon showing four subsequent transmigration steps: rolling (1), tethering (2), 
adhesion (3) and transmigration (4). (Adapted from Springer 1994). 
The first transmigration step is mediated by selectin binding. Selectins from one cell interact 
with sialylated carbohydrates on the other, opposing cell. E- and P-Selectin present on 
endothelial cells loosely bind to sialyl LewisX related carbohydrates on leukocytes and P-
selectin glycoprotein ligand-1 (PSGL-1). L-selectin is present on all circulating leukocytes 
and binds to CD34, PSGL-1 and sialyl LewisX on endothelial cells. Loose binding of 
leukocytes to endothelial cells allows the cells to slow down and “roll” along the 
endothelium. It also facilitates the exposure to chemokines such as CCL-2, CXCL-8, CCL-5 
and CCL-3. Patients with LAD II lack biosynthesis of fucose, which plays a pivotal role for 
carbohydrate ligand binding. LAD II is a milder form of LAD, but underlines the importance 
of selectin binding within the immune system (Blankenberg, Barbaux et al. 2003).  
Chemokines play a pivotal role in the second transmigration step. Slow rolling leukocytes 
are directed by a chemokine gradient towards the dysfunctional endothelial site. The 
chemokine exposure triggers outside-in signalling events within leukocytes, which leads to 
integrin activation. Chemokines involved in leukocyte attraction and activation include 
CXCL-8 (neutrophils) and CCL-2 (monocytes). 
The activated integrins on the surface of leukocyte are now able to firmly bind to the 
adhesion molecules present on the inflamed endothelium. Strong adhesion is facilitated by 
the binding of ICAM-1 to LFA-1, VCAM-1 to VLA-4 and MADCAM-1 to 4ǃ7. The binding 
allows leukocytes to spread and slowly migrate over the endothelial cell monolayer in 
search of transmigration opportunities. The importance of ICAM-1 within the third 
transmigration step has been demonstrated in studies using anti-ICAM-1 blocking 
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antibodies or endothelial cells lacking ICAM-1 (Greenwood, Wang et al. 1995; Reiss and 
Engelhardt 1999; Lehmann, Jablonski-Westrich et al. 2003). 
The junction proteins PECAM-1, VE-cadherin, junctional adhesion molecules (JAMs) and 
CD99 are found in endothelial junctions. Their homophilic (PECAM-1, CD99 and JAMs) and 
heterophilic binding (JAMs with integrins) allow the formation of a tightly packed 
endothelial cell layer with very selective permeability (Ley, Laudanna et al. 2007). When 
leukocytes are firmly attached to the endothelium, they develop microvilli-like projections 
called podosomes, with which they probe the endothelial surface (Barreiro, Yanez-Mo et al. 
2002). These docking stations are rich in ICAM-1 and VCAM-1 and F-actin. Integrin binding 
initiates signalling events in endothelial cells, which is thought to lead to endothelial cell 
contraction and weakening of junctional bonds (reviewed by (van Buul and Hordijk 2004)). 
Studies using ICAM-1 deficient cells show reduced transmigration events, but not complete 
inhibition. This shows that ICAM-1 is involved in the final leukocyte transmigration step 
but not essential, similar to CD18 (Sligh, Ballantyne et al. 1993; Lehmann, Jablonski-Westrich 
et al. 2003). Once the junctional adhesion molecule bonds are released leukocytes are able to 
migrate into the underlying tissue (Springer 1994). 
Another very important event in which ICAM-1 plays a vital role is the immunological 
synapse. This event is characterised by three major events: junction formation, 
reorganisation and the formation of a stable immunological complex (Grakoui, Bromley et 
al. 1999). During the first step, the junction formation, close contact between an antigen 
presenting cell (APC) and T-cell is facilitated with the help of ICAM-1 and LFA-1. The 
binding of ICAM-1 to its ligand overcomes the steric hindrance from glycoproteins CD45 
and CD43 present on the cell surface for the T-cell receptor (TCR) complex and enables 
interaction with MHC-peptide present on APCs. In the event of low affinity between the 
TCR and MHC-peptide complex, the interactions between the two cells stops here. If the 
TCR and MHC-peptide complex show high affinity towards each other, a signal cascade is 
triggered, which leads to reorganisation of the molecules involved. TCR and MHC-peptide 
complexes move inwards towards the centre with the outwards moving LFA-1/ICAM-1 
molecules forming a tight circle around them. This reorganisation step allows the formation 
of a stable immunological complex. During this reorganisation and ring formation process, 
ICAM-1 polymerises, thereby exhibiting higher affinity binding to LFA-1. In addition, 
concentrating TCR-MHC-peptide complexes within the ring centre facilitates optimal 
communication between the cells and signalling cascade (Grakoui, Bromley et al. 1999). 
ICAM-1 has also been reported to act as costimulatory ligand during MHC I and MHC II 
restricted antigen presentation (Gaglia, Greenfield et al. 2000). 
ICAM-1 has been shown to be present in atherosclerotic lesions (Poston, Haskard et al. 1992) 
and involved in the progression of atherosclerotic lesions. The involvement of ICAM-1 in 
atherosclerosis has been demonstrated in apoE -/- mice deficient in ICAM-1, which had 
reduced lesion size (Nageh, Sandberg et al. 1997). Time course analysis revealed that ICAM-
1 is not only involved in the initial plaque formation but also in subsequent progression in 
mice (Bourdillon, Poston et al. 2000; Kitagawa, Matsumoto et al. 2002). These data were 
supported by results obtained in apoE -/- mice treated with anti-ICAM-1 neutralising 
antibodies (Patel, Thiagarajan et al. 1998).  
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3.4 Signalling via ICAM-1  
The Outside-in signalling event triggered by ICAM-1 multimerisation was discovered 
several years ago (Durieu-Trautmann, Chaverot et al. 1994; Rothlein, Kishimoto et al. 1994). 
Experimental methods to identify the mechanism underlying the signalling cascade include 
co-cultures of endothelial cells with leukocytes, immobilised fibrinogen and antibody-
crosslinking of ICAM-1 on the cell surface. The cytoplasmic tail of ICAM-1 does not contain 
any conventional intrinsic kinase activity or known protein-protein interaction domains, 
that could contribute to signalling cascades, but does contain a high number of positively 
charged amino acids and one tyrosine site (Lyck, Reiss et al. 2003). Adapter molecules, 
which have been linked to the signalling cascade depend partly on the vascular bed from 
which endothelial cells originate and the experimental in vitro model used. Molecules which 
have been associated with ICAM-1 include: alpha-actinin (Carpén, Pallai et al. 1992), ERM-
proteins (Wójciak-Stothard, Williams et al. 1999), cortactin (Durieu-Trautmann, Chaverot et 
al. 1994), beta-tubulin and glyceraldehyde-3-phsophate dehydrogenase (Federici, Camoin et 
al. 1996). The Src-homology domain 2 has been shown to bind in a phosphotyrosine 
dependent manner following the activation of ICAM-1 by fibrinogen (Pluskota, Chen et al. 
2000; Pluskota and D'Souza 2000). These findings were opposed by Lyck et al (Lyck, Reiss et 
al. 2003), who showed that brain EC lacking the phosphotyrosine within ICAM-1’s 
cytoplasmic tail are still capable of facilitating transmigration of T-cells. Activation of src-
kinase family members p53/p65lyn have been reported in B-cells following crosslinking of 
ICAM-1 (Holland and Owens 1997). 
The small GTPase rho, has been proposed as another important molecule in the ICAM-
signalling cascade and the resulting rearrangement of the actin cytoskeleton (Etienne, 
Adamson et al. 1998; Adamson, Etienne et al. 1999; Wójciak-Stothard, Williams et al. 1999; 
Thompson, Randi et al. 2002). Mutagenesis of a five amino acid fragment within the 
cytoplasmic tail identified RKIKK as an important sequence, which seemed to be involved 
in rho activation following ICAM-1 crosslinking by antibodies on the cell surface (Oh, Lee et 
al. 2007). Activation of rho has been shown to trigger phosphorylation of focal adhesion 
kinase, paxillin and p130 as well as activation of JNK (Etienne, Adamson et al. 1998). 
Production of reactive oxygen species, which is required for activation of src tyrosine kinase 
has been observed when crosslinking ICAM-1 on pulmonary microvascular EC (Wang, 
Pfeiffer et al. 2003). Activation of src kinase is required for initiating ERM-molecule ezrin 
and p38 MAPK kinase pathway. Further signalling components initiated by ICAM-1 
crosslinking on brain microvascular EC are intracellular calcium release and activation of 
protein kinase C, which are thought to lead to phosphorylation of cortactin (Etienne-
Manneville, Manneville et al. 2000).  
MAPK-kinase pathways ERK-1/2 and/or JNK have been shown to the triggered depending 
on experimental design and cell type (Etienne, Adamson et al. 1998; Sano, Nakagawa et al. 
1998; Lawson, Ainsworth et al. 1999; Lawson, Ainsworth et al. 2001). We have demonstrated 
that AP-1 activation is the result of ERK-1 activation (Lawson, Ainsworth et al. 1999), 
together with the ERK-dependent production and secretion of IL-8 and RANTES (Sano, 
Nakagawa et al. 1998) as well as upregulation of VCAM-1 on the cell surface (Lawson, 
Ainsworth et al. 1999; Lawson, Ainsworth et al. 2001). Recently we have also shown that 
patient auto-reactive antibodies against ICAM-1 can also cause endothelial cell signalling 
(Lawson, Holder et al. 2005).  
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3.5 Importance of ICAM-1 polymorphism in different vascular diseases  
Two single-base pair polymorphisms of ICAM-1 have been described, which are located in 
exon 4 and exon 6. The first modification in exon 4 substitutes the amino acid glycine with 
arginine at codon 241 within the third Ig-domain. The second polymorphic change is located 
within the 5th domain at codon 469 and replaces glutamic acid with lysine. Domain four and 
five do not bind any ligands, but are involved in the protein stability and therefore might 
affect ligand binding. The polymorphic substitution has been associated with coronary heart 
disease, myocardial infarction (Jiang, Klein et al. 2002) and peripheral artery disease 
(Gaetani, Flex et al. 2002) but larger studies are required to confirm the association. We have 
shown an increase in cell surface expression of both endogenous and transfected ICAM-1 
G241/E469 genotype, which may account for some of the genetic associations that have 
been reported (Holder 2008).  
4. Soluble ICAM-1  
A circulating form of ICAM-1 consisting of only the five extracellular Ig-domains has been 
identified. Soluble ICAM-1 (sICAM-1) lacks the transmembrane region and cytoplasmic tail 
of membrane bound ICAM-1.  
sICAM-1 has been detected in various body fluids including serum (Rothlein, Mainolfi et al. 
1991; Seth, Raymond et al. 1991), cerebrospinal fluid (Tsukada, Matsuda et al. 1993), 
synovial fluid (Mason, Kapahi et al. 1993), sputum (Chihara, Yamamoto et al. 1994), urine 
(Teppo, von Willebrand et al. 2001) and bronchoalveolar fluid (Shijubo, Imai et al. 1994). 
sICAM-1 is present in normal human serum at concentrations between 100-450 ng/ml 
(Gearing and Newman 1993), whilst elevated sICAM-1 has been found in serum from 
patients with cardiovascular disease, cancer, autoimmune disease and several studies have 
correlated serum levels of sICAM-1 with severity of disease (for review see (Witkowska and 
Borawska 2004)). 
The molecular weight of monomeric sICAM-1 varies between 80-110kDa depending on the 
level of glycosylation induced by the originating cell (Rothlein, Mainolfi et al. 1991). Studies 
have demonstrated that sICAM-1 is present in serum not only as monomer but also forms 
homo- and hetero-multimers with isoforms ranging from 240, 340 and over 500kDa 
(Rothlein, Mainolfi et al. 1991; Seth, Raymond et al. 1991).  
A variety of cells have been shown to express sICAM-1 including primary endothelial cells, 
human aortic smooth muscle cells, melanoma cells and hematopoietic cell lines, but no 
expression mechanism has been identified. Alternative splicing has been suggested as one 
mechanistic pathway for the production of sICAM-1 (Wakatsuki, Kimura et al. 1995). The 
inflammatory cytokines TNF-, IL-1 and IFN-Ǆ have been reported to induce shedding of 
sICAM-1 from the cell surface of different primary cells and cell lines (Becker, Dummer et al. 
1991; Leeuwenberg, Smeets et al. 1992; Pigott, Dillon et al. 1992; Fonsatti, Altomonte et al. 
1997; Leung 1999). Furthermore, several proteases including matrix metalloproteases (MMP) 
(Lyons and Benveniste 1998); Tarín, Gomez, et al. 2009), human leukocyte elastase 
(Champagne, Tremblay et al. 1998) and TNF- converting enzyme (TACE) (Tsakadze, Sithu 
et al. 2006) have been demonstrated to cleave sICAM-1 from the cell surface. The cleavage 
site on ICAM-1 seems to vary depending on cell type, glycosylation pattern and therefore 
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also on the proteases involved. Further analysis showed that cleavage of membrane  
bound ICAM-1 by MMP-13 is dependent on NO and might be part of NO-mediated 
atheroprotection (Tarín, Gomez et al. 2009).  
4.1 sICAM-1 as a biomarker in vascular disease  
Increased levels of sICAM-1 have been found in patients with cardiovascular disease, 
cancer, autoimmune disease. Studies investigating the involvement of sICAM-1 in tumour 
surveillance by interfering with T-cell and tumour interaction have demonstrated that levels 
of sICAM-1 correlated with tumour progression in melanoma (Giavazzi 1992) and colorectal 
cancer (Alexiou 2001). Increased levels of sICAM-1 have also been linked to progression of 
atherosclerotic lesions in apoE -/- mice (Kitagawa, Matsumoto et al. 2002). These findings 
were supported in clinical studies with patients suffering from coronary heart disease 
(Hwang, Ballantyne et al. 1997; Ridker, Hennekens et al. 1998). Investigation between 
different risk factors associated with atherosclerosis showed a link between intake of 
saturated fatty acids and elevated levels of sICAM-1 (Bemelmans, Lefrandt et al. 2002). 
Increased levels of sICAM-1 were also found in type 2 diabetic patients (Becker, van 
Hinsbergh et al. 2002). Serum levels of sICAM-1 in cardiovascular patients treated with 
statins were confirmed to be lower in some groups (Romano, Mezzetti et al. 2000; Blann, 
Gurney et al. 2001; Bickel, Rupprecht et al. 2002), whereas some studies could not find a 
significant reduction (Rauch, Osende et al. 2000; Jilma, Joukhadar et al. 2003). 
The use of sICAM-1 as a biomarker has lead to several studies with a range of different 
cardiovascular disease profiles and varying patient numbers. A significant correlation 
between future coronary artery disease events and elevated levels of sICAM-1 has been 
noted by several groups (Hwang, Ballantyne et al. 1997; Ridker, Hennekens et al. 1998; 
Malik, Danesh et al. 2001) but opposed by other studies (Ridker, Buring et al. 2001). Using 
sICAM-1 levels as biomarker for future secondary cardiovascular diseases in patients with 
coronary artery diseases again showed varying results with Blankenberg et al. (Blankenberg, 
Rupprecht et al. 2001) finding no significant correlation, a finding contradicted by others 
showing its potential as independent biomarker (Wallén, Held et al. 1999; Haim, Tanne et al. 
2002).  
Several genome studies have found a significant link on chromosome 19 close to the location 
of the ICAM-1 gene which might be responsible for elevated sICAM-1 levels (Kent, 
Mahaney et al. 2007; Bielinski, Pankow et al. 2008; Barbalic, Dupuis et al. 2010). 
Furthermore, Kent and colleagues (Kent, Mahaney et al. 2007) suggested the presence of 
SNPs within ICAM-1 to be involved in regulation of protein expression, function and its 
potential for cleavage. Several studies have examined the association of the SNPs within the 
ICAM-1 gene and sICAM-1 with atherosclerosis but have so far proved inconclusive (Tang, 
Pankow et al. 2007; Bielinski, Pankow et al. 2008; Bielinski, Reiner et al. 2011). Further 
clinical studies with larger patient numbers are required to clarify the situation.  
4.2 Pro-inflammatory signalling cascades initiated by sICAM-1   
Studies have reported that sICAM-1 binds competitively to ligands of membrane  
bound ICAM-1 such as LFA-1, mac-1 and human rhinovirus (Marlin, Staunton et al. 1990; 
Martin, Martin et al. 1993) and may therefore have potential as a therapeutic to block 
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leukocyte:endothelial interactions when administered at high concentrations. However, a 
number of studies have also shown that addition of sICAM-1 at a physiologically relevant 
concentration activates proinflammatory cascades and causes angiogenesis in different in 
vitro and in vivo models. Incubation of murine brain microvascular EC or astrocytes with 
sICAM-1 lead to the increased secretion of the proinflammatory chemokine MIP-2 via 
activation of src tyrosine kinase and Erk phosphorylation (Otto, Heinzel-Pleines et al. 2000; 
Otto, Gloor et al. 2002). Gho and colleagues investigated the effects of sICAM-1 on EC 
angiogenesis. They demonstrated that sICAM-1 stimulated chemotactic EC migration, EC 
tube formation on Matrigel and sprouting in an aortic ring assay (Gho, Kleinman et al. 1999) 
and stimulates tumor growth in vivo (Gho, Kim et al. 2001). These data suggest that sICAM-
1 could contribute to the progression of atherosclerosis and other chronic inflammatory 
diseases.   
4.3 sICAM-1 contributes to monocyte recruitment by endothelial cells under laminar 
flow  
Whilst the effect of sICAM-1 interaction with endothelium has been documented during 
static culture conditions, it is pertinent to investigate the biological effects of these 
interactions using a model of arterial flow to replicate the forces applied to EC under 
physiological conditions. We have used a parallel plate chamber and flow loop (see 
Macey, Wolf et al. 2009; Macey, Wolf et al. 2010; Lawson, Rose et al. 2010) to examine 
sICAM-1 mediated pro-inflammatory effects on human umbilical vein EC (HUVEC) 
acclimatised to arterial flow conditions. These may provide useful insights into the 
initiation of endothelial dysfunction and inflammatory activation that is a feature of 
atheroma progression. 
We subjected HUVEC to laminar flow of 10dyn/cm2 for 8h and analysed the cells for 
changes in Erk-1/-2 phosphorylation (phospho-Erk) as an indication of HUVEC activation 
after exposure of cells to flow for different times. As shown in Figure 5A the level of 
phospho-Erk was reduced to 42±7% after exposure to 10dyn/cm2 flow for 8h compared to 
HUVEC in static culture (p<0.001). Levels of phospho-Erk in HUVEC subjected to flow 
remained below phospho-Erk in equivalent static cultures for at least a further 24h (data not 
shown). sICAM-1 has been shown to induce phospho-Erk in mouse astrocytes in static 
culture (Otto, Gloor et al. 2002), we therefore examined the effect of sICAM-1 in HUVEC 
pre-exposed to 10dyn/cm2 flow. As seen in Figure 5B in HUVEC pre-exposed to flow for 
8hr followed by sICAM-1 incubation caused a transient elevation of phospho-Erk after 
15min (Figure 5B 292±28% of untreated flowed HUVEC p<0.01).  
In static cell culture, sICAM-1 at physiologically relevant concentrations has been reported 
to induce expression of pro-inflammatory mediators (Otto, Heinzel-Pleines et al. 2000; Otto, 
Gloor et al. 2002). mRNA levels of IL-8 and MCP-1 were significantly increased 1hr after 
exposure to sICAM-1 in HUVECs (figure 6A and B). However, we observed no significant 
effect of sICAM-1 on secretion of MCP-1 and IL-8 in HUVEC cultured under static 
conditions (Figure 6C and D). Secretion of both chemokines were significantly reduced in 
EC exposed to 10dyn/cm2 shear forces for 24h compared to static cultures (Figure 6C and D) 
after acclimatisation to shear stress as would be expected from previous reports (Metallo, 
Vodyanik et al. 2008). Addition of sICAM-1 to the culture media of HUVEC pre-exposed to 
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shear and with continued exposure to shear lead to a three fold increase in MCP-1 secretion 
(Figure 6C), but did not induce any changes in IL-8 levels (figure 6D). To determine whether 
sICAM-1 mediated phosphorylation of Erk-1/-2 is involved in the upregulation of MCP-1 
secretion, 1μM of the MEK inhibitor U0126 or its inactive analogue U0124 was added to 
HUVEC pre-exposed to flow and prior to addition of sICAM-1 to the flow medium. As seen 
in Figure 6E, there was no significant effect of U0124 on this (1949±123pg/ml sICAM-1 
induced secretion vs 1645±73.58 pg/ml in the presence of 1μM U0124 and sICAM-1 
p=0.1348 ns). In contrast, a significant reduction in secretion of MCP-1 was observed in cells 
pre-treated with 1μM U0126 prior to addition of sICAM-1 (1141±128.4pg/ml, p=0.0177 
compared to cells treated with sICAM-1 alone; p=0.0039 compared to cells treated with 1μM 
U0124 before sICAM-1 (Figure 6E)). 
 
Fig. 5. sICAM-1 mediated Erk-1/-2 phosphorylation in HUVEC. A. HUVEC were 
subjected to laminar shear forces of 10dyn/cm2 for 8h in a parallel plate flow chamber and 
recirculating flow loop, or cells from the same isolate were maintained in static culture. 
Protein was harvested and phospho-Erk was measured by western blotting and 
immunodetection (anti-phospho-Erk-1/-2 antibody from Cell Signaling Inc.), followed by 
stripping of blots and detection of total Erk expression (anti-total-Erk-1/-2 antibody from 
Cell Signaling Inc.). Representative blots shown. Stimulation index was calculated from 
densitometry measured for each replicate and pooled from n=3 sets of replicates for each 
time point. B. HUVEC were subjected to laminar shear forces of 10dyn/cm2 for 8h in 
duplicate, before 100ng/ml sICAM-1 was added to one culture from each duplicate for 
indicated times. Protein was harvested and phospho-Erk was measured by western 
blotting and immunodetection followed by stripping of blots and detection of total Erk 
expression. Representative blots shown. Stimulation index calculated from densitometry 
measured for each replicate and pooled from n=3 sets of replicates for each time point. 
Pooled stimulation index data was used for paired T tests calculated using Prism. 
**p<0.01, ***p<0.001.  
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Fig. 6. Effect of sICAM-1 and shear stress on IL-8 and MCP-1 secretion in HUVEC. (A, B) 
mRNA for MCP-1 and IL-8 were measured in HUVEC in static culture following exposure 
to 100ng/ml sICAM-1 for 1hr. (C, D) HUVEC were grown in static culture or subjected to 
laminar shear forces of 10dyn/cm2 in a parallel plate flow chamber and recirculating flow 
loop for 16h to acclimatise before addition of 100ng/ml sICAM-1 for a further 24h. Secretion 
of MCP-1 and IL-8 were measured by ELISA. (E) HUVEC were acclimatised to shear stress 
for 16hr before addition of MEK inhibitor U0126 (1μM) or the inactive analogue U0124 
(1μM) followed by 100ng/ml sICAM-1 for 24hr. Secretion of MCP-1 and IL-8 were 
measured by ELISA. n=3 separate isolates for each pair of conditions. *p<0.05 and **p<0.01.  
5. Conclusions 
Our data suggest that the MEK-Erk pathway plays a role in sICAM-1 mediated MCP-1 
production in HUVEC pre-exposed to laminar flow, and therefore that cleavage of ICAM-1 
from the cell surface has a two fold effect; on the one hand providing a negative feedback 
mechanism to limit leukocyte adhesion and diapedesis, but on the other enhancing 
monocyte chemotaxis towards the endothelium. Thus sICAM-1 released into the circulation 
may be considered a pro-inflammatory mediator in the context of vascular inflammation 
and atherosclerosis progression. 
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At this time, no receptor has been identified for sICAM-1 and none of the common ligands 
for ICAM-1, such as LFA-1 and Mac-1, are present on HUVEC either in the activated or 
resting state. Two potential candidates for receptors have been suggested so far, namely the 
homophilic binding to membrane bound ICAM-1, or an unknown receptor of 49kD (Gho, 
Kleinman et al. 1999; Otto, Gloor et al. 2002). Otto et al showed that sICAM-1 did not bind to 
cell surface ICAM-1 using ICAM-1 deficient murine astrocytes but identified the 
involvement of an unidentified receptor (Otto, Gloor et al. 2002). It is possible that the level 
of expression of this unknown receptor on the cell surface could vary under different flow 
conditions, for example the receptor could be regulated through activation of a shear stress 
response element (SSRE) and therefore result in different expression levels on EC depending 
on the kinetics and/or type of shear stress to which the cells have been exposed. Since 
prolonged exposure to flow increases ICAM-1 expression (Nagel, Resnick et al. 1994; Chiu, 
Wung et al. 1997) and an SSRE has been identified in the promoter for ICAM-1 (Nagel, 
Resnick et al. 1994) we speculate that cell surface ICAM-1 could act as a receptor for sICAM-
1 in the experiments presented here. Further experiments are necessary using blocking FAb 
fragments to ICAM-1 to determine this.  
Experimental data obtained in vitro or in animal models together with data obtained from 
clinical samples indicates an important role for sICAM-1 within cardiovascular disease. 
More experimental studies are required to characterise the precise role of sICAM-1. By 
understanding the pathways and mechanisms involved in shedding sICAM-1 into the 
lumen and its role within the inflammation site, new potential methods to interfere with 
disease progression might become possible. In addition, larger clinical studies are also 
required to determine the potential use of sICAM-1 as non-invasive diagnostic biomarker 
for cardiovascular disease.   
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